Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT06698458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center clinical study enrolling up to 50 participants. The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V6. The secondary objectives of the study are to: * Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall and progression-free survival. * Assess pain control * Assess rate of surgical resection in Cohort 1.
Study identification
- NCT ID
- NCT06698458
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 50 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 16, 2025
- Primary completion
- Sep 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Aug 26, 2026
2025 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Recruiting |
| City of Hope | Goodyear | Arizona | 85338 | Not yet recruiting |
| Honor Health | Scottsdale | Arizona | 85258 | Recruiting |
| Cedars-Sinai | Los Angeles | California | 90048 | Not yet recruiting |
| Advent Health Cancer Institute | Orlando | Florida | 32804 | Not yet recruiting |
| Emory University | Atlanta | Georgia | 30308 | Recruiting |
| Bassett Healthcare Network | Cooperstown | New York | 13326 | Recruiting |
| NYU Langone Health | New York | New York | 10016 | Recruiting |
| Lenox hill Hospital | New York | New York | 10075 | Not yet recruiting |
| Montefiore Medical Center | The Bronx | New York | 10467 | Recruiting |
| Texas Oncology | Houston | Texas | 75251 | Not yet recruiting |
| Baylor College of Medicine | Houston | Texas | 77054 | Recruiting |
| University Cancer and Diagnostic | Houston | Texas | 77089 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06698458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06698458 live on ClinicalTrials.gov.